Drug Trial Radar · NCT01770145
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Dec 2012
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
Conditions
- Parkinson's Disease
- Motor Symptoms
- Akinesia
- Hypomobility
- Delayed Levodopa Onset
Interventions
APOKYNDrug
Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' "best on" UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).
L-dopaDrug
Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
TrimethobenzamideDrug
Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary.Time frame: L-Dopa Baseline Days 1-7 and APOKYN Treatment Days 1-7
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Keck School of Medicine
Los Angeles, California
Neurosearch, Inc.
Reseda, California
Georgetown University
Washington D.C., District of Columbia
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Rush University Medical Center
Chicago, Illinois
Henry Ford West Bloomfield Hospital
Bloomfield Hills, Michigan
Parkinson's Disease and Movement Disorders Center of New York
Commack, New York
University of Cincinnati Academic Health Center
Cincinnati, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
University of Texas Health Science Center, Houston, Department of Neurology
Houston, Texas
Center for Neurological Care and Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.